FibroGen, Inc.
FGENNASDAQHealthcare
$9.07
$-0.15(-1.63%)
Market Cap$36692186
P/E Ratio—
52W High$21.95
52W Low$4.85
FibroGen, Inc. (FGEN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FGEN · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 10, 2025EPS Actual
-$1.61
Est. -$4.01 · +59.9%
Revenue
$0.00B
Est. $0.00B · -35.6%
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 10, 2025
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
FGEN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 10, 2025 | -$4.01 | -$1.61 | +59.9% | $0.00B | $0.00B | -35.6% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$2.25 | -$3.38 | -50.2% | $0.00B | $0.00B | -53.5% |
| ▼ Q2 FY2025 | May 12, 2025 | $0.75 | -$4.00 | -633.3% | $0.00B | $0.00B | +37.0% |
| — Q1 FY2025 | Mar 17, 2025 | -$0.08 | -$0.08 | +0.0% | $-0.12B | $0.02B | -594.8% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.38 | -$0.17 | +55.3% | $0.05B | $0.02B | +129.1% |
| ▲ Q3 FY2024 | Aug 6, 2024 | -$0.26 | -$0.16 | +38.5% | $0.05B | $0.03B | +46.1% |
| ▼ Q2 FY2024 | May 6, 2024 | -$0.31 | -$0.33 | -6.5% | $0.06B | $0.04B | +52.5% |
| ▼ Q1 FY2024 | Feb 26, 2024 | -$0.42 | -$0.57 | -35.7% | $0.03B | $0.04B | -30.2% |
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$1.61
EPS Est.
-$4.01
EPS Surpr.
+59.9%
Revenue
$0.00B
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$3.38
EPS Est.
-$2.25
EPS Surpr.
-50.2%
Revenue
$0.00B
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$4.00
EPS Est.
$0.75
EPS Surpr.
-633.3%
Revenue
$0.00B
Q1 FY2025
Mar 17, 2025
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
$-0.12B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.17
EPS Est.
-$0.38
EPS Surpr.
+55.3%
Revenue
$0.05B
Q3 FY2024
Aug 6, 2024Beat
EPS Actual
-$0.16
EPS Est.
-$0.26
EPS Surpr.
+38.5%
Revenue
$0.05B
Q2 FY2024
May 6, 2024Miss
EPS Actual
-$0.33
EPS Est.
-$0.31
EPS Surpr.
-6.5%
Revenue
$0.06B
Q1 FY2024
Feb 26, 2024Miss
EPS Actual
-$0.57
EPS Est.
-$0.42
EPS Surpr.
-35.7%
Revenue
$0.03B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-4.01 | $-4.01 | $-4.01 | 1 |
| Q3 FY2027 | $-3.82 | $-3.82 | $-3.82 | 1 |
| Q2 FY2027 | $-3.85 | $-3.85 | $-3.85 | 1 |
| Q1 FY2027 | $-2.96 | $-2.96 | $-2.96 | 1 |
| Q4 FY2026 | $-4.40 | $-4.40 | $-4.40 | 1 |
| Q3 FY2026 | $-4.44 | $-4.44 | $-4.44 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2025 | Nov 10, 2025 | +59.9% | $11.03 | $11.00 | -0.27% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -50.2% | $8.71 | $8.37 | -3.90% |
| ▼ Q2 FY2025 | May 12, 2025 | -633.3% | $7.70 | $7.64 | -0.78% |
| ▲ Q1 FY2025 | Mar 17, 2025 | +0.0% | $10.98 | $11.13 | +1.37% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +55.3% | $8.47 | $9.66 | +14.05% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +38.5% | $11.38 | $11.00 | -3.34% |
| ▼ Q2 FY2024 | May 6, 2024 | -6.5% | $28.50 | $29.00 | +1.75% |
| ▼ Q1 FY2024 | Feb 26, 2024 | -35.7% | $45.50 | $46.25 | +1.65% |
Q4 FY2025-0.27%
Report Date
Nov 10, 2025
EPS Beat/Miss
+59.9%
Price Before
$11.03
Price After
$11.00
Q3 FY2025-3.90%
Report Date
Aug 11, 2025
EPS Beat/Miss
-50.2%
Price Before
$8.71
Price After
$8.37
Q2 FY2025-0.78%
Report Date
May 12, 2025
EPS Beat/Miss
-633.3%
Price Before
$7.70
Price After
$7.64
Q1 FY2025+1.37%
Report Date
Mar 17, 2025
EPS Beat/Miss
+0.0%
Price Before
$10.98
Price After
$11.13
Q4 FY2024+14.05%
Report Date
Nov 12, 2024
EPS Beat/Miss
+55.3%
Price Before
$8.47
Price After
$9.66
Q3 FY2024-3.34%
Report Date
Aug 6, 2024
EPS Beat/Miss
+38.5%
Price Before
$11.38
Price After
$11.00
Q2 FY2024+1.75%
Report Date
May 6, 2024
EPS Beat/Miss
-6.5%
Price Before
$28.50
Price After
$29.00
Q1 FY2024+1.65%
Report Date
Feb 26, 2024
EPS Beat/Miss
-35.7%
Price Before
$45.50
Price After
$46.25
Avg Beat Reaction+2.95%
Avg Miss Reaction-0.32%
Beat Rate4 / 8 quarters
Largest Move+14.05% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FGEN ends December
FibroGen, Inc. (FGEN) most recently reported earnings on November 10, 2025 for Q4 FY2025, posting EPS of $-1.61 — beating the analyst consensus of $-4.01 by +59.9%. The next FGEN earnings date is expected around September 1, 2026.
Each quarter, investors track FGEN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FGEN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FGEN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FGEN earnings · 5 questionsFibroGen, Inc.'s next earnings report is expected around September 1, 2026. FGEN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FGEN historically reports after market close (AMC).
FGEN earnings datewhen is FGEN earningsFGEN next earnings datewhen does FGEN report earningsFGEN earnings calendar
▸ Source: FMP · FibroGen, Inc. SEC filings · US GAAP · FibroGen, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026